John Tucker: Go ahead Steve.
Steve Parsons: Yes, so it’s doctor and patient kind of dependent, it depends on what they want. If they’re looking for expedited treatment, like they want to get on treatment tomorrow or the next day, we do that very well, 24 hours to 48 hours, the Docs have checked the expedited review on the start form. So that’s working very well. What people need to remember is, we have docs who order the product in advance of needing it. They submit the form, they get an approval for the product, they have a known copay, and then they have it ready in a queue until they want to pull it down or release it to the patient. And so, when you’re doing that, you have quite a variability in the fill rate, but it’s by design, it’s on purpose. So I’ll just answer the ones who want it quickly are getting it quickly.
Chase Knickerbocker: And maybe, do you guys kind of have visibility on how, what percentage of these filled and written scripts are — get us FUROSCIX now versus kind of writing and waiting for when these patients need it? Any sort of kind of split there that you can share?
Steve Parsons: Yes, I don’t have the actual number. That’s a good thing. I’ll have that for next time if there’s a question. But looking at the reports every day, it’s like 50-50. About 50% of people are seeking it as quickly as possible and they’re getting treatment. And then about 50% of them are just sending it in, getting answers. And they’re ready for when the patient needs it.
John Tucker: And we think that’s going to really play out, especially this quarter, as we get into the holidays and patients tend to be dietary non-compliant, medicine non-compliant. We hear from all the doctors, hey, we’re going to queue this up. I know Mrs. Jones is going to get in trouble with Thanksgiving. She always does. So we’re really seeing a lot of that this quarter and I think they’ll be able to pull them through this quarter as well.
Chase Knickerbocker: And I’m just going to sneak one more with you guys, apologies. But of those 400 that are still pending, is it fair for us to think that all of those are kind of the write and wait kind of scripts that we could still see come through?
John Tucker: I would say if you do the math calculation on what we published, there’s about 16% of all the prescriptions that were cancelled. The other 442 are — a lot of them have been queued and a bunch of them that were still pending not queued have been shipped in Q3. I’m sorry, Q4. As Q4 has evolved, we’ve shipped a lot of the pending ones.
Chase Knickerbocker: Helpful. Thanks, guys.
John Tucker: Thank you, Chase.
Operator: This concludes the question-and-answer session. I would like to turn the conference back over to John Tucker for any closing remarks. Please go ahead.
John Tucker: Okay. That concludes our call this afternoon. We remain very pleased with the trajectory of our FUROSCIX launch and the meaningful progress that we are making with large payers, and that should only add to our momentum as more heart failure patients gain affordable access to FUROSCIX. At the same time, we are excited about our lifecycle initiatives after having productive discussions with the FDA and look forward to providing more updates in 2024. Overall, I’m pleased with our progress and believe that we can build upon our current momentum and look forward to a successful 2024. Thank you again and have a good evening.
Operator: This concludes today’s conference call. You may disconnect your lines. Thank you for participating and have a pleasant day.
